Published News

Description: Experience quick and accurate diagnosis of your Apple devices at iCareExpert in South campus, Delhi. Our team of skilled technicians is well-versed in identifying hardware and software issues across a wide range of Apple products, including iPhones, iPads, MacBooks, and more. With our state-of-the-art diagnostic tools and expertise, we provide comprehensive assessments to determine the root cause of any problems. Visit us at Shop No A 101 Hari Nagar, Ashram, Delhi – 110014, near Ashram Metro Station, Exit Gate no. 2. Contact Harpreet at 8287300721 for reliable Apple device diagnosis services.

It’s medically proven that CBD has a lot of benefits; that’s why they need to be packed better. Custom CBD boxes are perfect for them because of the environmentally friendly material and the rest of the things.

Roots Analysis has done a detailed study on Bioavailability Enhancement Technologies and Services Market (2nd Edition), 2022-2035, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights  Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles  At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach  Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers  Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route  Industry stakeholders are steadily expanding their existing capabilities in order to enhance their respective service portfolios and drive compliance to evolving industry benchmarks  A rise in partnerships focused on bioavailability enhancement services and technology platforms validate the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions  In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions  5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby, indicating the rapid pace of research activity within this domain  Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio; we identified over 9,900 such patents  With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition  Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future  Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035  The estimated market opportunity is expected to be well distributed across different types of drug classes, dosage forms and key geographical regions. Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Key Questions Answered 1.4. Chapter Outlines 2. EXECUTIVE SUMMARY 3.1. Chapter Overview 3.2. Historical Overview of Bioavailability 3.3. Assessment of Drug Bioavailability 3.3.1. Key Considerations for Bioavailability and Assessment Studies 3.3.1.1. Absolute Bioavailability 3.3.1.2. Relative Bioavailability 3.3.1.3. Single and Multiple Dose Studies 3.3.2. Studies in Healthy Subjects and Patients 3.3.2.1. Different Bioavailability Assessment methods 3.4. Need for Bioavailability Enhancement 3.5. Factors Affecting Bioavailability 3.5.1. Drug Related Factors 3.5.2. Patient Physiology Related Factors 3.6. Bioavailability Enhancement Technologies 3.6.1. Physical Technologies for Bioavailability Enhancement 3.6.1.1. Solid Dispersion 3.6.1.1.1. Classification of Solid Dispersion Approaches 3.6.1.1.2. Methodologies for Solid Dispersion Approaches 3.6.1.1.2.1. Hot Melt Extrusion 3.6.1.1.2.2. Solvent Evaporation 3.6.1.1.2.3. Spray-Dried Dispersion 3.6.1.1.2.4. Other Techniques Used for Solid Dispersion 3.6.1.2. Nanosuspension Technology 3.6.1.2.1. Top-Down Approach 3.6.1.2.2. Bottom-Up Approach 3.6.2. Chemical Technologies for Bioavailability Enhancement 3.6.2.1. Lipid-Based Formulations 3.6.2.2. Non-Metal-Based Drug Delivery Systems 3.6.2.3. Polymer-Based Drug Delivery Systems 3.6.3. Biological Technologies for Bioavailability Enhancement 3.7. Concluding remarks 4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS 4.1. Chapter Overview 4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Bioavailability Enhancement Principle 4.2.5. Analysis by Bioavailability Enhancement Approach 4.2.5.1. Analysis by Solid Dispersion Approaches 4.2.5.2. Analysis by Size Reduction Approaches 4.2.5.3. Analysis by Lipid-Based Approaches 4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches 4.2.6. Analysis by Dosage Form 4.2.7. Analysis by Route of Administration 5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS 5.1. Chapter Overview 5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape 5.2.1. Analysis by Year of Establishment 5.2.2. Analysis by Company Size 5.2.3. Analysis by Location of Headquarters 5.2.4. Analysis by Company Size and Location of Headquarters 5.2.5. Leading Players: Analysis by Number of Technologies 5.3. Bioavailability Enhancement Technologies: Market Landscape 5.3.1. Analysis by Bioavailability Enhancement Principle 5.3.2. Analysis by Bioavailability Enhancement Approach 5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach 5.3.4. Analysis by Type of Molecule 5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule 5.3.6. Analysis by Dosage Form 5.3.7. Analysis by Route of Administration 5.3.8. Analysis by Availability for License 5.3.9. Analysis by Intellectual Property Rights 6. KEY INSIGHTS 6.1. Chapter Overview 6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation) 6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart) 6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation) 6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart) 6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation) 6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart) 7. COMPANY PROFILES 7.1. Chapter Overview 7.2. Adare Pharma Solutions 7.2.1. Company Overview 7.2.2. Recent Developments and Future Outlook 7.3. Ascendia Pharmaceuticals 7.3.1. Company Overview 7.3.2. Financial Overview 7.3.3. Recent Developments and Future Outlook 7.4. Catalent 7.4.1. Company Overview 7.4.2. Financial Overview 7.4.3. Recent Developments and Future Outlook 7.5. Formulex Pharma Innovations (formerly SoluBest) 7.5.1. Company Overview 7.5.2. Recent Developments and Future Outlook 7.6. Lonza 7.6.1. Company Overview 7.6.2. Financial Overview 7.6.3. Recent Developments and Future Outlook 7.7. Lubrizol Life Science Health 7.7.1. Company Overview 7.7.2. Financial Overview 7.7.3. Recent Developments and Future Outlook 7.8. Pace Analytical 7.8.1. Company Overview 7.8.2. Recent Developments and Future Outlook 7.9. Quotient Sciences 7.9.1. Company Overview 7.9.2. Recent Developments and Future Outlook 7.10. WuXi STA (A Subsidiary of WuXi AppTec) 7.10.1. Company Overview 7.10.2. Financial Overview 7.10.3. Recent Developments and Future Outlook 8. COMPANY BENCHMARK ANALYSIS 8.1. Chapter Overview 8.2. Company Benchmarking Analysis: Methodology 8.3. Company Benchmarking Analysis: Peer Groups 8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I) 8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II) 8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III) 8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV) 8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V) 8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI) 8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII) 8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII) 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. Bioavailability Enhancement: Partnerships and Collaborations 9.3.1. Analysis by Year of Partnership 9.3.2. Analysis by Type of Partnership 9.3.3. Analysis by Year and Type of Partnership 9.3.4. Analysis by Type of Partner 9.3.5. Analysis by Type of Partnership and Type of Partner 9.3.6. Most Active Players: Analysis by Number of Partnerships 9.4. Analysis by Geography 9.4.1. Analysis by Region 9.4.2. Analysis by Country 9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters 10. PUBLICATION ANALYSIS 10.1. Chapter Overview 10.2. Scope and Methodology 10.3. Bioavailability Enhancement: Publication Analysis 10.3.1. Analysis by Year of Publication 10.3.2. Analysis by Type of Publication 10.3.3. Analysis by Bioavailability Enhancement Approach 10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach 10.3.5. Most Popular Journals: Analysis by Number of Publications 10.3.6. Most Popular Journals: Analysis of Journal Impact Factor 10.3.7. Most Popular Publishers: Analysis by Number of Publications 10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications 10.3.9. Analysis by Popular Keywords 11. PATENT ANALYSIS 11.1. Chapter Overview 11.2. Scope and Methodology 11.3. Bioavailability Enhancement: Patent Analysis 11.3.1. Analysis by Application Year 11.3.2. Analysis by Publication Year 11.3.3. Analysis by Bioavailability Enhancement Approach 11.3.4. Analysis by CPC Symbols 11.3.5. Analysis by Geography 11.3.6. Analysis by Emerging Focus Areas 11.3.7. Analysis by Type of Organization 11.3.8. Leading Players: Analysis by Number of Patents 11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis 11.4.1. Analysis by Patent Characteristics 11.5. Bioavailability Enhancement Market: Patent Valuation Analysis 11.6. Leading Patents: Analysis by Number of Citations 12. CLINICAL TRIAL ANALYSIS 12.1. Chapter Overview 12.2. Guidelines To Conduct Bioavailability Studies 12.3. Bioavailability Enhancement: Clinical Trials Analysis 12.3.1. Research Methodology 12.3.2. Analysis of Trials by Trial Registration Year 12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year 12.3.4. Analysis of Trials by Study Design 12.3.5. Analysis of Trials by Trial Phase 12.3.6. Analysis of Trials by Trial Recruitment Status 12.3.7. Analysis of Trials by Type of Sponsor / Collaborator 12.3.8. Analysis by Type of Molecule and Trial Phase 12.3.9. Leading Industry Players: Analysis by Number of Registered Trials 12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials 12.3.11. Analysis by Study Focus 12.3.12. Analysis of Trials by Geography 12.3.13. Analysis of Enrolled Patient Population by Geography 13. TECHNOLOGY EVALUATION FRAMEWORK 13.1. Chapter Overview 13.2. Key Assumptions and Methodology 13.3. Technologies based on Solid Dispersion Approaches 13.3.1 List of Approved Drugs 13.3.2 Trends in Intellectual Capital 13.3.3. Trends in Research Activity 13.3.4. Business Model Adopted by Developers 13.4. Technologies based on Size Reduction Approaches 13.4.1 List of Approved Drugs 13.4.2 Trends in Intellectual Property 13.4.3. Trends in Research Activity 13.3.4. Business Model Adopted by Developers 13.5. Technologies based on Lipid-based Approaches 13.5.1 List of Approved Drugs 13.5.2 Trends in Intellectual Property 13.5.3. Trends in Research Activity 13.3.4. Business Model Adopted by Developers 13.6. Technology Evaluation Framework: Wind Rose Representation 13.7. Technology Evaluation Framework: Spider Web Representation 13.8. Results and Discussions 14. DEMAND ANALYSIS 14.1. Chapter Overview 14.2. Key Assumptions and Methodology 14.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 14.4. Analysis by Drug Class, 2022 and 2035 14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 14.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 14.5. Analysis by BCS Classification, 2022 and 2035 14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 14.6. Analysis by Dosage Form, 2022 and 2035 14.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 14.6.4. Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 14.7. Concluding Remarks 15. MARKET FORECAST AND OPPURTUNITY ANALYSIS 15.1. Chapter Overview 15.2. Forecast Methodology and Key Assumptions 15.3. Global Bioavailability Enhancement Services Market, 2022-2035 15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035 15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035 15.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035 15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035 15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035 15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035 15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035 15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches, 2022-2035 15.6.2. Bioavailability Enhancement Services Market for Size Reduction Approaches, 2022-2035 15.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Approaches, 2022-2035 15.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, 2022-2035 15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035 15.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035 15.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035 15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035 15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035 15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035 15.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035 15.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035 15.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035 15.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035 15.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035 15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035 15.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035 15.9. Concluding Remarks 16. CONCLUSION 17. APPENDIX I: LIST OF COMPANIES 18. APPENDIX II: TABULATED DATA Get more details on the Bioavailability Enhancement Technologies and Services Market report https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html You may also be interested in the following titles: DNA Encoded Libraries Cell Therapy Media, Cell Therapy Kits, Cell Therapy Reagents and Cell Therapy Surface Market About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 [email protected]

Discover the ins and outs of the popular ThunderCrash gambling game. Learn tips and strategies for maximizing your chances of success, and explore the best online casinos to play Thunder Crash!

electric single motor desk

Qatar Airways will not let you book a short trip online, no matter what. This is because when kids fly, they have their own needs. A parent or legal adult will need to call 1-571-389-6426 to talk to FondTravels Qatar Airways.

Parents who use Allegiant Air to take their kids on vacation will have a great time. Do you have plans to go somewhere soon? Call +1 (571) 389 6426, which is Allegiant Air's Friendly Travels line, to make cheap and easy ticket bookings.

Product catalogs have always been an essential tool for sales and marketing. Custom wholesale catalogs are a fantastic way to help customers become informed about your products. Digital catalogs are as suitable as they have been easy to share and connect and help you to save on printing and distribution costs. In the end, the companies raise their brand awareness and increase sales. If you are wondering how you can make the best use of wholesale catalogs for your business, here are some essential features that will make things clear:

Business cards foster a brand image in the minds of the customer. It would help if you crafted a professional impression when working on cards and cardholders. You have undoubtedly created the best business card stack, but where to store them? Custom business card boxes are the perfect solution for you. They save and organize your valuable business card and contact details. Although many general options are available in the market, they do not position your brand. Generic options do not have the potential to deliver value according to the needs of your business. Customized business card boxes also give your office table top a personalized look. They seamlessly persuade a potential customer that walks right into your office.

Custom packaging is a great way to make your product stand out on the shelf and in your customer’s minds. Whether you have a range of products that need to be displayed or want to create an exclusive look for your products, custom packaging can help. You can choose the size and shape of the box. Moreover, you can also customize the graphics printed on it and the materials used. There are endless possibilities when customizing your product packaging. Custom cereal boxes provide extra assurance that the product is of a good standard and is being handled carefully.